Awakn Life Sciences Archives

Dave HodesMarch 28, 2022

Human beings seek treatment for any addiction to any substance (or any behavioral act) that is affecting their social development and their ability to lead a productive life. While these issues have been part of mental health treatment for decades, there is still much work to be done. Enter the psychedelics industry, which is discovering […]

Dave HodesFebruary 15, 2022

While there is more and more work on psychedelics to treat people for drug and tobacco addiction, it’s treating alcoholism that is gaining new interest from psychedelics researchers today. But finding that specific psychedelics treatment to slow down alcoholism, or even stop it completely, continues to be a head-scratcher for psychedelics researchers. Help is desperately […]

Debra BorchardtJanuary 11, 2022

Awakn Life Sciences Corp. (OTCQB: AWKNF) reported positive data from its Phase II A/B trial. It was the first controlled trial to investigate Ketamine-Assisted Therapy for the Treatment of Alcohol Use Disorder (AUD), the results have been published in the American Journal of Psychiatry. Awakn said the double-blind placebo-controlled trial included 96 patients with severe AUD, […]

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

In other news

The Daily Hit: January 4, 2024

Connecticut Attorney General Tells Unlicensed Cannabis Events Company to Stop

Testing Concerns Lead to Quarantine for 70% of Mississippi MMJ Goods

Tag: Awakn Life Sciences

Awakn Tackles Addictions Beyond Alcoholism

The Holy Grail of Psychedelics Research: Treating Alcoholism

Awakn Reports Positive Results For Ketamine Alcohol Treatment Study

The Daily Hit - TEST TEST TEST

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

Get the latest cannabis news delivered right to your inbox